Deafness after COVID-19?

Since December 2019, the coronavirus disease 2019 (COVID-19) pandemic has changed the world and the health system. At the time of writing, more than 103,377,424 cases of infection have been confirmed worldwide, with many people battling the sequelae months after recovering from a COVID-19 infection. The long-term sequelae of COVID-19 have hardly been investigated thus far.

Case report

Anamnesis

After contracting COVID-19 in early April, a 38-year-old man initially showed symptoms of a respiratory infection, including subjectively reduced olfactory function. In the course of the infection, there was rapidly increasing dyspnea. Mechanical ventilation was required 6 days after the initial symptoms as well as veno-venous extracorporeal membrane oxygenation (ECMO), because of acute lung failure. The transfer to our university hospital took place 5 days later. On the basis of suspected septicemia due to a bacterial superinfection, antibiotic infusion therapy was initiated using amoxicillin, which was then switched to meropenem. Furthermore, dialysis was necessary because of acute renal failure. After another 6 weeks of intensive therapy and prolonged sleep–awakening, the patient complained of hearing loss in the right ear, deafness and tinnitus in the left ear, as well as rotatory vertigo. The presence of other symptoms, such as otalgia, otorrhea, and vertigo, was denied. The patient’s pre-existing conditions were morbid obesity and arterial hypertension.

Clinical findings

Otoscop y was unremarkable on both sides. Results of the tuning fork test (Weber/Rinne) could not be obtained, since the patient was unable to hear the tones. Spontaneous or provocation nystagmus was not present.

Diagnosis

The first pure-tone audiometry after 45 days of intensive care in Freiburg at the bedside revealed an air conduction threshold on the right side of 70 dB between 1 kHz and 4 kHz. On the left side there was no air conduction threshold. Measurement of otoacoustic emissions (OAE) did not show reproducible potentials on both sides. The diagnostic tests were completed using brainstem audiometry (BERA), videoystagmography (VNG), computed tomography (CT), and magnet resonance tomography (MRI). The BERA showed no potentials on the left side. On the right side the threshold for Jewett V was 70 dB with normal interpeak latency; VNG demonstrated under-excitability on the left side. The MRI findings were unremarkable with no signs of an inflammatory process in the cochlea (Fig. 1).

The diagnoses of acute deafness in the left ear and profound hearing loss in the right ear were made.

Treatment course

Furosemide (2 × 20 mg/day), which was applied to stimulate self-diuresis 2 days before the appearance of hearing loss, was immediately withdrawn.

After 46 days of intensive care, directly after the complaint was reported and the diagnosis was made, bilateral intratympanic cortisone therapy (Fortecortin 4 mg) and systemic cortisone administration (prednisolone 250 mg) over 3 days were initiated. Audiometric follow-up 1 week after initiation of therapy showed no improvement in hearing (Fig. 2).

Cochlea implant (CI) surgery on the left side was indicated and performed without complications. Due to profound hearing loss in the right ear, a hearing aid was fitted. The hearing rehabilitation with CI and hearing aid restored the patient’s communication ability, which was necessary for the urgently needed neurological rehabilitation.

The patient achieved 100% understanding of numbers and 65% understanding of monosyllables at 65 dB with CI on the left side 4 months after surgery. On the right side, hearing was unchanged (Fig. 3).
The COVID-19 disease, first described in December 2019, is caused by infection with SARS-CoV2, a novel RNA beta-coronavirus. The long-term sequelae and the effect of a COVID-19 infection on the sensory organs in otorhinolaryngology have hardly been investigated thus far [3].

Otorhinolaryngological symptoms such as sore throat and dyspnea might indicate a COVID-19 infection [2]. At the same time, an impaired sense of smell occurs in COVID-19-infected patients. Bocksberger et al. reported that an impaired sense of smell is not associated with rhinitis symptoms in the majority of cases, which may point to a neurogenic cause [4].

Little is known particularly about the influence of a COVID-19 infection on hearing and the labyrinthine system. Mustafa reported significantly impaired high-tone thresholds and reduced OAE amplitudes with respect to the hearing of COVID-19 patients compared with non-infected individuals [9].

As an etiological factor of the pronounced, irreversible hearing loss in the previously normal-hearing 38-year-old patient, a SARS-CoV2-associated sequela in the framework of a COVID-19 infection was considered. Various hypotheses for the pathomechanism of impaired hearing as part of a COVID-19 infection are possible and will be considered here.

In addition to a systemic infection as part of septicemia, a local infection such as labyrinthitis may have resulted in inner-ear damage in our patient. Influenza viruses can cause an infection of the perilymph spaces; accordingly, SARS-CoV2 infection could also cause hearing loss and affect the vestibular organ by direct intralabyrinthine viral manifestation. It is suspected that the blood–labyrinth barrier is disrupted at the peak of infection. The antigen–antibody complex or immune response to viral infection may cause sensory hearing loss in the period of abatement after an acute COVID-19 infection, which occurs within 3 or 4 weeks [10]. Furthermore, labyrinthitis
can lead to fibrosis and ossification of the cochlea, which may complicate or even prevent implantation of a CI electrode carrier. Therefore, prompt implantation before the obliteration process is advised [8]. The presence of rotatory vertigo and under-excitability of the left vestibular organ was suggestive of labyrinthitis in our patient.

To verify this hypothesis, inner ear fluid was obtained intraoperatively from the patient for virological examination; no viral RNA was identified. At the same time, the patient’s serum showed a highly positive IgG value (8.4/positive) against SARS-CoV2. The patient had thus already formed antibodies, which might explain why no viral RNA was found in the inner ear fluid at the time of the operation.

Another explanation for the pathomechanism could be the thromboembolic potential of the virus. Al-Ani et al. reported elevated D-dimer levels in COVID-19 patients with serious respiratory courses. It is assumed that the SARS-CoV2 virus promotes thrombotic complications [1, 9]. Hearing loss could thus arise as a thromboembolic complication due to cochlear perfusion impairment caused by a SARS-CoV2 infection.

It should be considered that increased vasculitis is observed in SARS-CoV2 infections, which are associated with an elevated risk of stroke [4]. The brain MRI study of our patient showed no ischemic change, and thus vasculitis was not assumed in this case.

Herold et al. reported elevated cytokine and interleukin (IL)-6 values in COVID-19 patients. It is currently being examined whether IL-6 is only a marker of disease activity or perhaps a central factor in the inflammation process COVID-19 infections [7]. Such a possible cytokine storm could result in functional impairment and organ failure, including of the labyrinth with resultant deafness. The IL-6 laboratory values of our patient were in the normal range during the COVID-19 infection.

It should also be taken into account that hearing loss caused by a COVID-19 viral infection might be brought about by an infection of the nerve sheaths and brain regions. A neuroinvasive potential similar to that already known for coronaviruses is suspected for SARS-CoV2 [3]. Regarding the cause of the loss of smell, it is assumed that the virus enters the rhinencephalon directly via the filiae olfactoriae and then spreads to other regions of the brain. Bocksberger et al. assumed a neurogenic cause of the changes in the olfactory sense caused by COVID-19 infection [4]. Local inflammation of individual brain regions, elicited by the virus, could also cause a central loss of hearing, as is known for an impaired sense of smell. The effect of the SARS-CoV2 virus on the auditory system has not yet been investigated [5]. Damage to auditory neuronal structures in our patient is not likely due to very good hearing rehabilitation with the CI. The present diagnostic tests also showed damage to the patient’s hair cells in the postinfectious absence of OAE. As a differential diagnosis, cochlea disorder due to ototoxic medication (furosemide) must be taken into account, whereby such hearing loss is rarely irreparable, especially with rapid and long-term i.v. medication [6]. Furosemide was immediately withdrawn after 2 days when hypacusis was reported, but there was no improvement in the hearing loss. Rare hearing loss, but not deafness, has been described in association with ECMO therapy [11].

Other reasons that may be considered among the causes of sensory-neural hearing loss—such as acoustic trauma, noise-induced hearing loss, head trauma, labyrinth concussion, diabetes mellitus, hyperlipidemia, presbycusis, disorders such as Meniere’s disease, and otosclerosis—could be excluded from the patient’s medical history [10].

Ultimately, the cause of the hearing loss associated with the COVID-19 infection in this patient has not yet been unequivocally determined.

**Practical conclusion**

- An effect of a COVID-19 infection on the auditory system is possible.
- Audiometric testing of COVID-19-infected patients is urgently recommended.
Fig. 3 A Postoperative pure-tone audiometry and Freiburg Speech Test 4 months after CI surgery on the left side.

References

1. Al-Ania F, Chehadea S, Lazo-Langnerab A (2020) Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res 192:152–160
2. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, Rodríguez-Jorge F, Natera-Villalba E, Gómez-Corral J, Gómez-López A, Monreal E, Parra-Díaz P, Cortés-Cuevas IL, Galán JC, Fraga-ol-Amau C, Porta-Ettessam J, Masjuan J, Alonso-Cánovas A (2020) Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case–control study. Eur J Neurol 27(9):1738
3. Berger JR (2020) COVID-19 and the nervous system. J Neurovirol 26:143–148
4. Bocksberger S, Wagner W, Hummel T, Guggemos W, Seilmaier M, Hoelscher M, Wendtner C-M (2020) Temporary hyposmia in COVID-19 patients. HNO 68:440–443. https://doi.org/10.1007/s00106-020-00891-4
5. Bösel J, Berlit P (2020) Neurological effects of COVID-19. DG Neuro 11:1–7
6. Chen J, Zhenzhen L, Yan H, Xing W, Mi W, Wang R, Li W, Chen F, Qiu J, Zha D (2020) miR-182 prevented ototoxic deafness induced by co-administration of kanamycin and furosemide in rats. Neurosci Lett 732:134861
7. Herold T, Jurinovic V, Arneich C, Lipworth B, Hellmuth J, Bergwelt-Baldon M, Klein M, Weinberger T (2020) Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 146:128–136
8. Lenarz T (2017) Cochlear implant — state of the art. GMS Curr Top Otorhinolaryngol. Head Neck Surg 16:Doc4
9. Mustafa MWM (2020) Audiological profile of asymptomatic Covid-19 PCR-positive cases. Am J Otolaryngol 41(3):102483
10. Satar B (2020) Criteria for establishing an association between Covid-19 and hearing loss. Am J Otolaryngol 41(6):102658
11. Boyle K, Felling R, Yu A, Battarjee W, McElrath Schwartz J, Salorio C, Bembea M (2018) Neurologic Outcomes After Extracorporeal Membrane Oxygenation—a Systematic Review. Pediatr Crit Care Med 19(8):763–766